Cubist Systematic Strategies, LLC Karuna Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$161.01 - $317.85 $2.34 Million - $4.63 Million	14,560 New	14,560 $4.61 Million
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $571,100 - $778,072	3,239 New	3,239 $702,000
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $5.61 Million - $6.94 Million	-29,312 Reduced 97.27%	822 $161,000
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $2.7 Million - $6.05 Million	21,824 Added 262.62%	30,134 $6.78 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $710,601 - $1.08 Million	-7,562 Reduced 47.64%	8,310 $1.05 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $412,709 - $552,380	4,173 Added 35.67%	15,872 $2.01 Million
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $402,508 - $579,897	3,638 Added 45.13%	11,699 $1.53 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $633,410 - $787,820	6,259 Added 347.34%	8,061 $986,000
Q2 2021 Aug 16, 2021	SELL	$107.45 - $135.95 $47,600 - $60,225	-443 Reduced 19.73%	1,802 $205,000
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $214,307 - $298,764	2,245 New	2,245 $270,000
Q4 2020 Feb 16, 2021	SELL	$75.23 - $109.23 $234,115 - $339,923	-3,112 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$71.31 - $109.74 $90,421 - $139,150	1,268 Added 68.76%	3,112 $241,000
Q2 2020 Aug 14, 2020	BUY	$62.14 - $117.21 $114,586 - $216,135	1,844 New	1,844 $206,000
Q1 2020 May 15, 2020	SELL	$60.41 - $115.92 $232,276 - $445,712	-3,845 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$11.44 - $123.99 $21,255 - $230,373	-1,858 Reduced 32.58%	3,845 $290,000
Q3 2019 Nov 14, 2019	BUY	$16.05 - $27.35 $91,533 - $155,977	5,703 New	5,703 $93,000

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account